ArticleJournal of medicinal chemistry2023
4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1
Open access · hybridAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Dual-target carbonic anhydrase inhibitors in cancer therapy: progress, challenges, and opportunities.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- (Journal of medicinal chemistry · 2026Article
- Synthesis and Characterization of Sulfonamide-Schiff Bases, and Investigation of Cytotoxic, Antioxidant, HDAC, and Apoptotic Activities in Human Colon Cancer Cells (DLD-1 and HT-29).Archiv der Pharmazie · 2026Article
- Article
- Opposite effects of spermidine and GC7 in cell culture are dictated by distinct molecular targets.The Biochemical journal · 2025Article
- Disturbance of bile acids profile aggravates the diarrhea induced by capecitabine through inhibiting the Wnt/β-catenin pathway.Journal of advanced research · 2025Article
- Design, synthesis, andRSC advances · 2024Article
- Discovery of new tricyclic spiroindole derivatives as potent P-glycoprotein inhibitors for reversing multidrug resistance enabled by a synthetic methodology-based library.RSC medicinal chemistry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 6 institutions in 2 countries.
Domiziana MasciDepartment of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome 00168, Italy.
Michela PuxedduLaboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
Laura Di MagnoLaboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.
Michele D'AmbrosioLaboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
Anastasia ParisiLaboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
Marianna NalliLaboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
Ruoli BaiMolecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.
Antonio ColucciaLaboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.ORCID 0000-0002-7940-8206
Pietro SciòLaboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
Viviana OrlandoDepartment of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
Sara D'AngeloDepartment of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
Stefano BiagioniDepartment of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
Andrea UrbaniDepartment of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome 00168, Italy.
Ernest HamelMolecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.
Alessio NocentiniDipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Universitá degli Studi di Firenze, Via Ugo Schiff 6, Sesto Fiorentino I-50019, Firenze, Italy.ORCID 0000-0003-3342-702X
Serena FilibertiExperimental Oncology and Immunology Unit, Department of Molecular and Translational Medicine, University of Brescia, Via Branze 39, Brescia 25123, Italy.
Marta TuratiExperimental Oncology and Immunology Unit, Department of Molecular and Translational Medicine, University of Brescia, Via Branze 39, Brescia 25123, Italy.
Roberto RoncaExperimental Oncology and Immunology Unit, Department of Molecular and Translational Medicine, University of Brescia, Via Branze 39, Brescia 25123, Italy.
Joanna KopeckaDepartment of Oncology and Molecular Biotecnology Center "Guido Tarone″, Oncological Pharmacology Unit, Via Nizza 44, Torino 10126, Italy.
Chiara RigantiDepartment of Oncology and Molecular Biotecnology Center "Guido Tarone″, Oncological Pharmacology Unit, Via Nizza 44, Torino 10126, Italy.ORCID 0000-0001-9787-4836
Cinzia FiondaLaboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.
Rosa BordoneLaboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.
Giorgia Della RoccaLaboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.
Gianluca CanettieriLaboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.
Claudiu T SupuranDipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Universitá degli Studi di Firenze, Via Ugo Schiff 6, Sesto Fiorentino I-50019, Firenze, Italy.ORCID 0000-0003-4262-0323
Romano SilvestriLaboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.ORCID 0000-0003-2489-0178
Giuseppe La ReginaLaboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.ORCID 0000-0003-3252-1161
Istituto Pasteur · ITSapienza University of Rome · ITUniversity of Brescia · ITNational Institutes of Health · USUniversità Cattolica del Sacro Cuore · ITUniversity of Florence · IT
Funding
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
Abstract
We synthesized new pyrrole and indole derivatives as human carbonic anhydrase (hCA) inhibitors with the potential to inhibit the Wnt/β-catenin signaling pathway. The presence of both
Indexed as
Carbonic AnhydrasesNeoplasmsBenzenesulfonamidesCarbonic Anhydrase InhibitorsCarbonic Anhydrase IXDrug Resistance, MultipleDrug Resistance, NeoplasmHumansMolecular StructureStructure-Activity RelationshipWnt Signaling PathwayBenzenesulfonamidesCarbonic Anhydrase InhibitorsCarbonic Anhydrase IXCarbonic Anhydrases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.